Doctors hail LCZ696 , a new drug for heart failure
Yet-unnamed drug likely to be included in new treatment guidelines
Published on Sep 4, 2014 6:34 AM
A drug that has yet to hit the market, and does not even have a proper name, is likely to be included in Singapore's newest heart failure treatment guidelines.
Cardiologists revising the guidelines, which are for all doctors, are in favour of including LCZ696 because of its impressive performance in a clinical trial.
The guidelines are revised every four to five years, and the latest set is expected by the end of the year.
Results of a large clinical trial, presented at the European Cardiology Congress over the weekend, show LCZ696 more than doubled survival rates compared with the best treatments available today. It also reduced hospitalisation by 21 per cent.
To continue reading, log in if you are a subscriber
If you are not a subscriber, you can get instant, unlimited access here